A phytochemical from broccoli sprouts shows neuroprotective effects in epilepsy, ASD, Alzheimer’s and Parkinson’s
There is a compound that broccoli produces to protect itself. Not to protect the person who eats it: to survive the threats of its own environment, from pathogens to physical injury. Yet that same plant defense mechanism, once transformed in the human body, activates molecular pathways capable of protecting the nervous system from some of its most severe biological aggressions.
Sulforaphane is not a new trend in nutraceuticals. It is an isothiocyanate identified in the laboratories of Johns Hopkins University in the early 1990s, when researchers isolated it from Brassicaceae sprouts as a potent inducer of phase II detoxification enzymes. Since then, the scientific literature has progressively expanded its pharmacological profile to include a growing area of interest: neuroprotection.
A review published in July 2025 in Frontiers in Cellular Neuroscience by Bessetti and Litwa of East Carolina University systematically reconstructs the mechanisms through which sulforaphane can exert neuroprotective effects, analyzing cell studies, animal models, and clinical trials in major neurological disorders.
Mechanism of action of sulforaphane: the NRF2-KEAP1 pathway
The cornerstone of sulforaphane’s pharmacology is its ability to activate the transcription factor NRF2 (Nuclear Factor Erythroid 2-related Factor 2). Under basal conditions, NRF2 is sequestered in the cytosol by the protein KEAP1, which promotes its ubiquitination and proteasomal degradation.
Sulforaphane covalently modifies the cysteine residues of KEAP1, preventing this degradation. NRF2 is released, translocates to the nucleus, and binds to ARE (Antioxidant Response Element) sequences, inducing the transcription of key antioxidant enzymes: glutathione-S-transferase (GST), NAD(P)H quinone oxidoreductase 1 (NQO1), and heme oxygenase-1 (HO-1).
The result is a coordinated enhancement of cellular defenses against oxidative stress. In neurons, which have high metabolic demand and limited regenerative capacity, this action has direct clinical relevance.
Sulforaphane and neuroinflammation: inhibition of the NF-κB pathway
Why is sulforaphane relevant in neurological disorders? The answer lies in the direct link between oxidative stress and neuroinflammation.
NRF2 activation suppresses the NF-κB pathway, which drives the production of pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6. In cell models, this translates into a reduction of M1-type microglial activation and a shift toward the M2 phenotype, oriented toward tissue repair and cellular debris clearance.
In murine models of chronic stress, sulforaphane prevented the increase of pro-inflammatory cytokines, promoted physiological microglial branching, and reduced the loss of dendritic spines. The concurrent reduction of MeCP2, a negative regulator of BDNF, suggests a potential impact on long-term synaptic plasticity as well.
Epilepsy: preclinical data and mitochondrial role
In epilepsy models, sulforaphane has shown a consistent and reproducible activity profile. In neuronal cultures subjected to extracellular magnesium removal, co-administration attenuated reactive oxygen species production and prevented neuronal death through a dose-dependent induction of glutathione.
In animal models with kainic acid, post-seizure treatment restored levels of reduced glutathione (GSH) and contained neuronal death in vulnerable areas. In lithium-pilocarpine status epilepticus models, sulforaphane improved mitochondrial bioenergetics and reduced markers of oxidative damage, with effects documented in both immature and adult animals.
To date, no registered clinical trials exist for this indication, representing a significant gap in the available scientific literature.
Autism spectrum disorder: clinical and biological evidence
ASD is the area with the highest number of published clinical studies on sulforaphane. The trial by Singh et al. (2014) in 44 young males with ASD showed significant improvements on the Aberrant Behavior Checklist and Social Responsiveness Scale after 18 weeks of treatment, with statistically significant differences compared to placebo starting from week ten.
Subsequent studies produced mixed results. Some confirmed positive trends on specific subscales of socialization and communication; others, in younger age groups (3–7 years), did not find significant differences. The variables at play concern patient age, dosage, form of administration, and rating scales used.
A biologically relevant finding emerges from the study by Zimmerman et al. (2021): in patients treated with glucoraphanin, plasma concentrations of IL-6 and TNFα were significantly reduced at week 15, independently of behavioral scores. An objective biological response, even in cases where clinical scales do not record statistically significant changes.
Alzheimer’s and Parkinson’s: preclinical basis for formulation
In preclinical models of Alzheimer’s disease, sulforaphane reduced the accumulation of amyloid oligomers and tau phosphorylation in PS1V97L mice, improving cognitive performance and increasing the expression of mitochondrial antioxidant enzymes. In cortical neuron cultures, concentrations of 0.1 μM proved neuroprotective, with increased cell viability and preservation of dendritic structures in the presence of oligomeric Aβ.
In Parkinson’s disease, MPTP and 6-OHDA models documented the preservation of tyrosine hydroxylase-positive dopaminergic neurons, reduction of astrogliosis and microgliosis, and improved motor performance. NRF2-dependent activation was identified as the central mechanism: in NRF2 knockout animals, the protective effects of sulforaphane disappear.
Glucoraphanin and bioavailability: formulation considerations
On the practical level, the form of administration has a direct impact on biological efficacy. The precursor glucoraphanin, chemically more stable than sulforaphane, offers superior bioavailability when formulated with active myrosinase, as in freeze-dried broccoli sprout capsules. This combination maximizes enzymatic conversion at the intestinal level.
Clinical trials with the most consistent results have predominantly used glucoraphanin preparations with active myrosinase. A formulation finding with direct industrial implications: the choice of ingredient and production process has a decisive impact on the biological efficacy of the final product.
Why does sulforaphane show a hormetic profile in neurons?
In vitro literature consistently shows a hormetic profile of sulforaphane: low doses (0.01–0.1 μM) induce neuroprotection, while higher concentrations can become cytotoxic to neuronal cells. In microglia, concentrations of 50 μM significantly reduced cell viability.
In cortical neurons, the peak of protection was recorded at 0.1 μM, with loss of effect at 10 μM. Neuronal cells are more sensitive to sulforaphane than tumor cells. Defining the therapeutic range in nutraceutical formulations for neurological use requires a specific approach, distinct from that established in oncology.
If your company is interested in developing formulations based on sulforaphane or glucoraphanin:
Source: Bessetti RN and Litwa KA (2025) Broccoli for the brain: a review of the neuroprotective mechanisms of sulforaphane. Front. Cell. Neurosci. 19:1601366. doi: 10.3389/fncel.2025.1601366
